Revvity, Element Biosciences collaborate to commercialize IVD solution

Revvity (RVTY) announced a strategic agreement to commercialize an in vitro diagnostic workflow solution for neonatal sequencing, co-developed with Element Biosciences. The collaboration involves the co-development of a comprehensive IVD solution tailored for newborn sequencing. Additionally, customers will have immediate access to a research use only version of the newborn sequencing research workflow.